Rec'd 3/7/2011

March 7, 2011

Karen Midthun, M.D.
Presiding Officer
Center for Biologics Evaluation and Research
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20854

Re: Docket No. FDA 2010-N-0621 - Avastin (bevacizumab)

Dear Dr. Midthun:

Thank you for your letters regarding the Avastin matter. You have asked us to submit a joint statement of facts that are not in dispute and issues that are disputed by March 23, 2011. To enable a more productive collaboration between CDER and Genentech, we are writing to respectfully request a 15-day extension of that deadline, as well as the deadline for identifying any confidential information that will be used and proposing how it should be handled and commenting on the proposed hearing schedule provided in your March 3, 2011 letter. By our calculations, granting such an extension would make the new deadline April 7, 2011. Accordingly, we would also like to request an extension of the April 20, 2011 deadline for each party's submission of its summary of arguments. If our request is granted, the new deadline for those submissions would be May 5, 2011.

Sincerely,

Carla M. Cartwright, Esq.
Office of Chief Counsel
Food and Drug Administration

Michael S. Labson, Esq.
Covington & Burling LLP
Counsel for Genentech, Inc.

cc: Laurie Lenkel
Donald O. Beers, Esq.

FDA-2010-N-0621

EXT